WO2000001440A3 - Methods for treating neurological injuries and disorders - Google Patents

Methods for treating neurological injuries and disorders Download PDF

Info

Publication number
WO2000001440A3
WO2000001440A3 PCT/US1999/015106 US9915106W WO0001440A3 WO 2000001440 A3 WO2000001440 A3 WO 2000001440A3 US 9915106 W US9915106 W US 9915106W WO 0001440 A3 WO0001440 A3 WO 0001440A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
disorders
treating neurological
neurological injuries
treatment
Prior art date
Application number
PCT/US1999/015106
Other languages
French (fr)
Other versions
WO2000001440A2 (en
Inventor
Mark Marchionni
Michael Jarpe
Ted Ebendal
Original Assignee
Cambridge Neuroscience Inc
Mark Marchionni
Michael Jarpe
Ted Ebendal
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cambridge Neuroscience Inc, Mark Marchionni, Michael Jarpe, Ted Ebendal filed Critical Cambridge Neuroscience Inc
Priority to AU53902/99A priority Critical patent/AU771437B2/en
Priority to EP99939649A priority patent/EP1094863A4/en
Priority to KR1020017000235A priority patent/KR20010079503A/en
Priority to CA002336718A priority patent/CA2336718A1/en
Priority to JP2000557884A priority patent/JP2002519394A/en
Publication of WO2000001440A2 publication Critical patent/WO2000001440A2/en
Publication of WO2000001440A3 publication Critical patent/WO2000001440A3/en
Priority to US09/756,481 priority patent/US6872698B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/48—Nerve growth factor [NGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Abstract

The present invention relates to methods for treatment of nerve cell death (degeneration) and neurodegenerative diseases. Methods of the invention include administering an effective amount of GDF-1 alone or in combination with neurotrophin-3, to a patient in need of such treatment such as a person suffering from stroke or traumatic brain injury or a neurodegenerative disease.
PCT/US1999/015106 1998-07-06 1999-07-02 Methods for treating neurological injuries and disorders WO2000001440A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
AU53902/99A AU771437B2 (en) 1998-07-06 1999-07-02 Methods for treating neurological injuries and disorders
EP99939649A EP1094863A4 (en) 1998-07-06 1999-07-02 Methods for treating neurological injuries and disorders
KR1020017000235A KR20010079503A (en) 1998-07-06 1999-07-02 Methods for treating neurological injuries and disorders
CA002336718A CA2336718A1 (en) 1998-07-06 1999-07-02 Methods for treating neurological injuries and disorders
JP2000557884A JP2002519394A (en) 1998-07-06 1999-07-02 Methods for treating nerve damage and disorders
US09/756,481 US6872698B2 (en) 1998-07-06 2001-01-08 Methods for treating neurological injuries and disorders

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US9179198P 1998-07-06 1998-07-06
US60/091,791 1998-07-06

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US09/756,481 Continuation US6872698B2 (en) 1998-07-06 2001-01-08 Methods for treating neurological injuries and disorders

Publications (2)

Publication Number Publication Date
WO2000001440A2 WO2000001440A2 (en) 2000-01-13
WO2000001440A3 true WO2000001440A3 (en) 2000-04-20

Family

ID=22229675

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1999/015106 WO2000001440A2 (en) 1998-07-06 1999-07-02 Methods for treating neurological injuries and disorders

Country Status (6)

Country Link
EP (1) EP1094863A4 (en)
JP (1) JP2002519394A (en)
KR (1) KR20010079503A (en)
AU (1) AU771437B2 (en)
CA (1) CA2336718A1 (en)
WO (1) WO2000001440A2 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE322506T1 (en) * 2004-01-19 2006-04-15 Ares Trading Sa METHOD FOR PURIFYING PROTEINS EXPRESSED IN BACTERIA
JPWO2008133141A1 (en) * 2007-04-24 2010-07-22 東洋紡績株式会社 Osmotin recombinant protein, method for producing the same, and use thereof

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5635372A (en) * 1995-05-18 1997-06-03 Genetics Institute, Inc. BMP-15 compositions
US5652118A (en) * 1991-03-11 1997-07-29 Creative Biomolecules, Inc. Nucleic acid encoding a novel morphogenic protein, OP-3
US5767252A (en) * 1996-04-08 1998-06-16 The Johns Hopkins University School Of Medicine Neuronal cell growth factor, Narp

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992000382A1 (en) * 1990-06-15 1992-01-09 Carnegie Institution Of Washington Gdf-1

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5652118A (en) * 1991-03-11 1997-07-29 Creative Biomolecules, Inc. Nucleic acid encoding a novel morphogenic protein, OP-3
US5635372A (en) * 1995-05-18 1997-06-03 Genetics Institute, Inc. BMP-15 compositions
US5767252A (en) * 1996-04-08 1998-06-16 The Johns Hopkins University School Of Medicine Neuronal cell growth factor, Narp

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
FARKAS ET AL.: "Characterization of growth/differentiation factor 5 (GDF-5) as a neurotrophic factor for cultured neurons from chicken dorsal root ganglia", NEUROSCI. LETT., vol. 236, 1997, pages 120 - 122, XP002926436 *
See also references of EP1094863A4 *

Also Published As

Publication number Publication date
EP1094863A4 (en) 2005-02-02
WO2000001440A2 (en) 2000-01-13
JP2002519394A (en) 2002-07-02
AU771437B2 (en) 2004-03-25
EP1094863A2 (en) 2001-05-02
AU5390299A (en) 2000-01-24
CA2336718A1 (en) 2000-01-13
KR20010079503A (en) 2001-08-22

Similar Documents

Publication Publication Date Title
WO2002036829A3 (en) Methods of diagnosing, preventing and treating neurological disorders and neuronal injuries
WO2001009118A3 (en) Dithiolthione compounds for the treatment of neurological disorders and for memory enhancement
AU2001273574A1 (en) Substituted 5-alkynyl pyrimidines having neurotrophic activity
EP1140104A4 (en) Methods for increasing cytidine levels in vivo and treating cytidine-dependent human diseases
WO2004060146A3 (en) Method of treatment for central nervous system injury
EP0792156A4 (en) Methods for the prevention or treatment of vascular hemorrhaging and alzheimer's disease
BRPI0417959A (en) antibody or functional fragment thereof, pharmaceutical composition, method for treating or prophylaxis of stroke and other neurological disorders / disorders in a human, use of an anti-goat antibody, and methods for inhibiting neurodegeneration and / or promoting recovery function in a human patient, to promote axonal growth, to produce an antifungal antibody and to produce an intravenously administered pharmaceutical composition
WO2005006945A3 (en) Methods for treating neural disorders and compounds useful therefor
AU4331400A (en) Neurotrophic substituted pyrimidines
WO2003092617A3 (en) Combinations for the treatment of inflammatory skin disorders
WO2004110360A3 (en) Proteoglycan degrading mutants for treatment of cns
WO2004096216A3 (en) Use of a topical medicament comprising riluzole
WO1999060021A3 (en) Use of activated t cells, nervous system-specific antigens for treating disorders of the nevrous system
WO2000033814A3 (en) Method for administering agents to the central nervous system
WO2000066068A3 (en) Method for inducing growth and enhancing survival of nervous tissue
WO2005014041A3 (en) Use of an amyloid beta dna vaccine for the treatment and/or prevention of amyloid diseases
BG104466A (en) Application of substituted aminomethyl chromans in order to prevent neural degeneration and to promote neural regeneration
WO2000057865A3 (en) Pharmaceutical compositions comprising cyclic glycerophosphates and analogs thereof for promoting neural cell differentiation
WO2000012045A3 (en) Method for treating neurodegenerative disorders
AP9901473A0 (en) Use of benzopyranols to treat neurological disorders.
WO2005046605A3 (en) Compositions and methods of treating neurological diseases
WO1999056666A8 (en) The treatment of sexual dysfunction in certain patient groups
WO2000001440A3 (en) Methods for treating neurological injuries and disorders
IL130586A0 (en) IL6RIL6 chimera for the treatment of demyelinating diseases
AU5659798A (en) Therapeutic composition comprising the kal protein and use of the kal protein for the treatment of retinal, renal, neuronal and neural injury

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI GB GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

ENP Entry into the national phase

Ref document number: 2336718

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1020017000235

Country of ref document: KR

ENP Entry into the national phase

Ref country code: JP

Ref document number: 2000 557884

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 53902/99

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 1999939649

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999939649

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020017000235

Country of ref document: KR

WWW Wipo information: withdrawn in national office

Ref document number: 1020017000235

Country of ref document: KR

WWG Wipo information: grant in national office

Ref document number: 53902/99

Country of ref document: AU

WWW Wipo information: withdrawn in national office

Ref document number: 1999939649

Country of ref document: EP